Vol 8, No 4 (2017)
Review paper
Published online: 2018-02-24

open access

Page views 1015
Article views/downloads 1732
Get Citation

Connect on Social Media

Connect on Social Media

Erythroferrone — a new hormone regulating production of hepcidin

Edyta Knap, Beata Jakubowska-Solarska, Magdalena Nieśpiałowska
Hematologia 2017;8(4):265-270.

Abstract

Iron is an essential bioelement for life, however both a deficiency and overload can lead to serious disorders in body function. Different proteins are involved in maintaining systemic iron homeostasis. Many of these have already been well-described, and some are commonly used markers for assessing iron metabolism. In 2014, a new protein was identified, erythroferrone, which suppresses hepcidin synthesis while increasing the availability of iron that is essential for erythropoiesis. The paper is therefore aimed at presenting current knowledge on the structure, function and the potential
uses of erythroferrone.

Article available in PDF format

View PDF (Polish) Download PDF file

References

  1. Kautz L. L’érythroferrone, un régulateur érythroïde du métabolisme du fer. Médecine/Sciences. 2014; 30(10): 834–836.
  2. Lipiński P, Starzyński R, Styś A, et al. Heme metabolism as an integral part of iron homeostasis. Post Hig Med Dośw. 2014; 68: 557–570.
  3. Wierzbicka D, Gromadzka G. Ceruloplasmin, hephaestin and zyklopen: the three multicopper oxidases important for human iron metabolism. Post Hig Med Dośw. 2014; 68: 912–924.
  4. Artym J. Udział laktoferryny w gospodarce żelazem w organizmie. Część I. Wpływ laktoferryny na wchłanianie, transport i magazynowanie żelaza. Post Hig Med Dośw. 2008; 62: 599–611.
  5. Sokołowska E, Klimek J. Hepcydyna — hormon uczestniczący w regulacji metabolizmu żelaza w organizmie. Post Biol Komórki. 2007; 34: 15–30.
  6. Lawen A. Is erythroferrone finally the long sought-after systemic erythroid regulator of iron? World J Biol Chem. 2015; 6(3): 78–82.
  7. Arosio P. New signaling pathways for hepcidin regulation. Blood. 2014; 123(10): 1433–1434.
  8. Camaschella C, Pagani A, Nai A, et al. The mutual control of iron and erythropoiesis. Int J Lab Hematol. 2016; 38 Suppl 1: 20–26.
  9. Filipczyk L, Król P, Wystrychowski A. Hepcydyna — hormon wątrobowy kontrolujący homeostazę żelaza. Forum Nefrol. 2010; 3: 233–242.
  10. Kautz L, Jung G, Valore EV, et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014; 46(7): 678–684.
  11. https://www.ncbi.nlm.nih.gov/gene/151176 (26.04.2017).
  12. Seldin MM, Peterson JM, Byerly MS, et al. Myonectin (CTRP15), a novel myokine that links skeletal muscle to systemic lipid homeostasis. J Biol Chem. 2012; 287(15): 11968–11980.
  13. Łukaszczyk E, Małyszko J. Żelazo w chorobach nerek. Kosmos. 2014; 63: 367–371.
  14. Kautz L, Jung G, Nemeth E, et al. Erythroferrone contributes to recovery from anemia of inflammation. Blood. 2014; 124(16): 2569–2574.
  15. Jiang X, Gao M, Chen Y, et al. EPO-dependent induction of erythroferrone drives hepcidin suppression and systematic iron absorption under phenylhydrazine-induced hemolytic anemia. Blood Cells Mol Dis. 2016; 58: 45–51.
  16. Cucuianu A, Patiu M, Trifa AP, et al. Redistribution of iron towards deposits in erythroblastopenic anemia as a consequence of decreased erythroferrone production. Med Hypotheses. 2014; 83(5): 530–532.
  17. Kuragano T, Shimonaka Y, Kida A, et al. Determinants of hepcidin in patients on maintenance hemodialysis: role of inflammation. Am J Nephrol. 2010; 31(6): 534–540.
  18. van der Weerd NC, Grooteman MPC, Bots ML, et al. CONTRAST Investigators. Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients. Nephrol Dial Transplant. 2013; 28(12): 3062–3071.
  19. Honda H, Kobayashi Y, Onuma S, et al. Associations among erythroferrone and biomarkers of erythropoiesis and iron metabolism, and treatment with long-term erythropoiesis-stimulating agents in patients on hemodialysis. PLoS One. 2016; 11(3): e0151601.
  20. Ciniselli CM, De Bortoli M, Taverna E, et al. Plasma hepcidin in early-stage breast cancer patients: no relationship with interleukin-6, erythropoietin and erythroferrone. Expert Rev Proteomics. 2015; 12(6): 695–701.
  21. Kautz L, Jung G, Du X, et al. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia. Blood. 2015; 126(17): 2031–2037.
  22. Moura IC, Hermine O. Erythroferrone: the missing link in β-thalassemia? Blood. 2015; 126(17): 1974–1975.
  23. Latour C, Wlodarczyk MF, Jung G, et al. Erythroferrone contributes to hepcidin repression in a mouse model of malarial anemia. Haematologica. 2017; 102(1): 60–68.



Hematology in Clinical Practice